<DOC>
	<DOCNO>NCT02831972</DOCNO>
	<brief_summary>An Open-Label , 2-Period , Fixed Sequence Study Determine Effect Multiple Oral Doses Itraconazole Single Dose Pharmacokinetics AG 120 Healthy Adult Subjects . Period 1 consist single oral dose AG-120 administer Hour 0 follow PK sample 504 hour ( 21 day ) . In Period 2 , multiple oral dos itraconazole administer daily ( QD ) 18 consecutive day single oral dose AG-120 coadministered Hour 0 Day 1 . PK sample AG-120 take 504 hour ( 21 day ) follow AG-120 dose Day 1 .</brief_summary>
	<brief_title>Drug-Drug Interaction Study AG120 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>1 . Healthy , adult , male female , 18 55 year age , inclusive , screen . 2 . Continuous non smoker use nicotine containing product least 3 month prior first dose throughout study . 3 . BMI ≥ 18.5 ≤ 32.0 kg/m2 screening . 4 . Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign ECGs , deem PI designee . 5 . For female childbearing potential : either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : nonhormone release intrauterine device least 3 month prior first dose either physical ( e.g . condom , diaphragm , ) chemical ( e.g. , spermicide ) barrier method time screen throughout study . surgical sterilization partner ( vasectomy 4 month minimum first dose/dosing ) either physical ( e.g . condom , diaphragm , ) chemical ( e.g. , spermicide ) barrier method time screen throughout study . two physical barrier method ( e.g . condom , diaphragm , ) spermicide least 14 day prior first dose throughout study . In addition , female subject childbearing potential advise remain sexually inactive keep birth control method least 90 day follow last dose . 6 . For female non childbearing potential : must undergo one follow sterilization procedure least 6 month prior first dose : hysteroscopic sterilization ; bilateral tubal ligation bilateral salpingectomy ; hysterectomy ; bilateral oophorectomy . postmenopausal amenorrhea least 1 year prior first dose follicle stimulate hormone ( FSH ) serum level consistent postmenopausal status per PI designee judgment . 7 . A non vasectomized , male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug . ( No restriction require vasectomized male provide vasectomy perform 4 month prior first dose study drug . A male vasectomized less 4 month prior study first dose must follow restriction non vasectomized male ) . 8 . If male , must agree donate sperm first dose 90 day last dose . 9 . Understands study procedure inform consent form ( ICF ) , willing able comply protocol . 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical psychiatric condition disease opinion PI designee . 3 . History illness , opinion PI designee , might confound result study pose additional risk subject participation study . 4 . History presence alcoholism drug abuse within past 2 year prior first dose . 5 . History presence hypersensitivity idiosyncratic reaction study drug ( ) relate compound . 6 . History presence ventricular dysfunction risk factor Torsades de Pointes ( e.g. , heart failure , cardiomyopathy , family history Long QT Syndrome ) . 7 . Female subject positive pregnancy test lactating . 8 . Positive urine drug alcohol result screen check . 9 . Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) . 10 . QTcF interval &gt; 450 msec ( male ) &gt; 460 msec ( female ) ECG finding deem abnormal clinical significance PI designee screening . 11 . Unable refrain anticipates use : Any drug , include prescription non prescription medication , herbal remedy , vitamin supplement begin 14 day prior first dose throughout study . Acetaminophen ( 2 g per 24 hour period ) may permit study . Any drug know significant inducer CYP enzymes and/or P gp , include St. John 's Wort , 28 day prior first dose throughout study . Appropriate source consult PI designee confirm lack PK/pharmacodynamic interaction study drug ( ) . 12 . Has diet incompatible study diet , opinion PI designee , within 28 day prior first dose throughout study . 13 . Donation blood significant blood loss within 56 day prior first dose . 14 . Plasma donation within 7 day prior first dose . 15 . Participation another clinical study within 28 day prior first dose . The 28 day window derive date last blood collection dosing , whichever later , previous study Day 1 Period 1 current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>